1. Home
  2. RWAY vs ENTA Comparison

RWAY vs ENTA Comparison

Compare RWAY & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Runway Growth Finance Corp.

RWAY

Runway Growth Finance Corp.

HOLD

Current Price

$6.85

Market Cap

321.2M

Sector

N/A

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$12.57

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RWAY
ENTA
Founded
2015
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
321.2M
374.6M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
RWAY
ENTA
Price
$6.85
$12.57
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$9.86
$20.40
AVG Volume (30 Days)
470.2K
170.9K
Earning Date
03-12-2026
02-09-2026
Dividend Yield
19.91%
N/A
EPS Growth
N/A
29.93
EPS
N/A
N/A
Revenue
N/A
$102,814,000.00
Revenue This Year
$6.75
$7.76
Revenue Next Year
$5.12
N/A
P/E Ratio
$5.70
N/A
Revenue Growth
N/A
16.48
52 Week Low
$6.61
$4.09
52 Week High
$11.41
$17.15

Technical Indicators

Market Signals
Indicator
RWAY
ENTA
Relative Strength Index (RSI) 27.79 40.63
Support Level N/A $12.09
Resistance Level $9.53 $15.52
Average True Range (ATR) 0.22 0.81
MACD -0.03 -0.17
Stochastic Oscillator 15.61 2.50

Price Performance

Historical Comparison
RWAY
ENTA

About RWAY Runway Growth Finance Corp.

Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: